Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 7/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749404 | 0.92 | PRCP (0.45) | LMNATSHRNPSR1PRCPPDE2A | |
| SCHEMBL14749431 | 0.91 | LMNA (0.56) | LMNATSHRNPSR1PRCPALDH1A1 | |
| SCHEMBL14749406 | 0.89 | PRCP (0.48) | LMNATSHRNPSR1PRCPPDE2A | |
| SCHEMBL14749378 | 0.83 | PRCP (0.49) | PRCPPDE2AHRH3 | |
| SCHEMBL14749419 | 0.82 | PRCP (0.51) | LMNATSHRNPSR1PRCPHRH3 | |
| SCHEMBL14749430 | 0.81 | PRCP (0.51) | LMNATSHRNPSR1PRCPHRH3 | |
| SCHEMBL14736597 | 0.81 | PRCP (0.48) | LMNATSHRNPSR1PRCPALDH1A1 | |
| SCHEMBL14749425 | 0.80 | PRCP (0.47) | LMNATSHRNPSR1PRCP | |
| SCHEMBL14749442 | 0.80 | PRCP (0.44) | LMNATSHRNPSR1PRCPALDH1A1 | |
| SCHEMBL14749429 | 0.79 | LMNA (0.46) | LMNATSHRNPSR1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | LMNA 3736/4885TSHR 3548/4885NPSR1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.